The Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients.
Oral antidiabetics
amylase
dipeptidyl peptidase-4 inhibitors
lipase
Journal
Turkish journal of pharmaceutical sciences
ISSN: 2148-6247
Titre abrégé: Turk J Pharm Sci
Pays: Turkey
ID NLM: 101717890
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
21
08
2018
accepted:
25
10
2018
entrez:
27
5
2020
pubmed:
27
5
2020
medline:
27
5
2020
Statut:
ppublish
Résumé
In different studies, it has been shown that the use of dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4 inh) does not increase the risk of pancreatitis or pancreatic cancer. Although the number of studies involving clinical pancreatitis clinics is sufficient, the number of studies involving clinical non-pancreatitis hyperamylasemia is rare. The aim of the study was to investigate the relationship between DPP-4 inh usage and amylase and lipase increment without clinical pancreatitis symptoms. Eighty-seven patients who met the inclusion criteria were enrolled. The patients were divided into 3 groups according to their use of saxagliptin, sitagliptin, or vildagliptin. All patients included in the study were receiving metformin at a dose of 2 g/day. Fasting blood glucose, postprandial blood glucose, HbA1C, serum creatinine, ALT, amylase, and lipase results were recorded at the beginning of treatment and at the end of 3 months. There was an increase in all groups in terms of amylase and lipase values but there was no significant difference between the groups in terms of increase (p>0.05) There was no statistically significant increase in the saxagliptin and vildagliptin groups (p>0.05) when the baseline and 3-month values of lipase and amylase increase were examined. However, there was a statistically significant increase in amylase and lipase in the sitagliptin group (p<0.05). The use of DPP-4 inh can increase amylase and lipase levels without clinical findings of acute pancreatitis in the patient. DPP-4 inh should be used with caution in patients at risk for pancreatitis and pancreatic cancer. Patients using DPP-4 inh, especially sitagliptin, should be evaluated carefully for pancreatitis risk factors.
Identifiants
pubmed: 32454763
doi: 10.4274/tjps.galenos.2018.83788
pii: 20273
pmc: PMC7227863
doi:
Types de publication
Journal Article
Langues
eng
Pagination
68-73Informations de copyright
©Copyright 2020 Turk J Pharm Sci, Published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflicts of interest: No conflict of interest was declared by the authors.
Références
N Engl J Med. 2013 Oct 3;369(14):1327-35
pubmed: 23992602
Diabetes. 2012 May;61(5):986-8
pubmed: 22517653
Diabetes Obes Metab. 2007 Mar;9(2):194-205
pubmed: 17300595
Diabetes. 2013 Oct;62(10):e16-7
pubmed: 24065798
Histochemie. 1966;7(3):197-201
pubmed: 5959122
Diabetes Obes Metab. 2015 Apr;17(4):430-4
pubmed: 25146418
N Engl J Med. 2014 Feb 27;370(9):794-7
pubmed: 24571751
Drug Saf. 2014 Jul;37(7):521-8
pubmed: 24859164
Diabetes Metab. 2008 Feb;34 Suppl 2:S65-72
pubmed: 18640588
Gastroenterology. 2011 Jul;141(1):150-6
pubmed: 21334333
Gastroenterology. 2010 Mar;138(3):1166-77
pubmed: 20026066
BMJ. 2014 Apr 15;348:g2366
pubmed: 24736555
Gastroenterology. 2011 Jul;141(1):20-3
pubmed: 21723985
Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1076-86
pubmed: 20923958
Diabetes. 2013 Oct;62(10):e19-22
pubmed: 24065800
Diabetes. 2012 May;61(5):989-90
pubmed: 22517654
Mediators Inflamm. 2010;2010:592760
pubmed: 20652060
Diabetes Care. 2010 Feb;33(2):453-5
pubmed: 20103562
Diabetes. 2013 Oct;62(10):e18
pubmed: 24065799
Eur J Biochem. 1993 Jun 15;214(3):829-35
pubmed: 8100523
Diabetes Res Clin Pract. 2013 Jun;100(3):e66-9
pubmed: 23618553
Diabetes. 2009 Sep;58(9):2148-61
pubmed: 19509017
Diabetes. 2012 May;61(5):1250-62
pubmed: 22266668
Circulation. 2008 Jan 29;117(4):574-84
pubmed: 18227398